Previous 10 | Next 10 |
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that DecisionDx-SCC can independently risk-stratify patients with cutaneous squamous cell carcinoma (SCC) and one or more risk factors a...
The Sun Bus will make a stop at Castle’s headquarters in the Houston area on Monday, May 16 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that for the second year, it is a national...
Castle Biosciences, Inc. (CSTL) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of Investor Relations and Corporate Communications Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Of...
Castle Biosciences press release (NASDAQ:CSTL): Q1 GAAP EPS of -$0.97 misses by $0.26. Revenue of $26.86M (+17.8% Y/Y) beats by $1.63M. For further details see: Castle Biosciences GAAP EPS of -$0.97 misses by $0.26, revenue of $26.86M beats by $1.63M
Q1 2022 revenue increased 18% over Q1 2021 to $26.9 million Q1 2022 adjusted revenue increased 50% over Q1 2021 to $26.3 million Delivered 8,627 total test reports in Q1 2022, an increase of 68% compared to Q1 2021 DecisionDx-Melanoma test report volume increased 48%...
To kick off Mental Health Awareness Month, Schrier shares her story on how genetic testing and the IDgenetix® test can help match genes with medications to improve treatment outcomes Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative ...
Castle is proud to collaborate with the Melanoma Research Foundation and The Skin Cancer Foundation in support of key advocacy events during the month of May Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care,...
The diagnostics firm Castle Biosciences (NASDAQ:CSTL) announced on Friday that the Veterans Health Administration (VHA) expanded its U.S. federal supply contract with the company to offer coverage for its entire skin cancer test portfolio. VHA awarded Castle (CSTL) a five-year U.S. Federal su...
Castle was first awarded a U.S. Federal Supply Schedule contract in August 2021 for DecisionDx®-Melanoma Castle’s expanded U.S. Federal Supply Schedule contract now includes DecisionDx®-SCC, DecisionDx® DiffDx™-Melanoma, myPath® Melanoma and D...
The study data reinforce the value of TissueCypher in helping physicians and patients make more informed management decisions based on the unique biology of individual patients’ esophageal biopsies Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health th...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...